IMI2 - Call 13

IMI2 – Call 13 was launched on 30 November 2017 with the following topics:

  • Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
  • Genome-environment interactions in inflammatory skin disease
  • The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
  • Mitochondrial dysfunction in neurodegeneration
  • Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
  • A sustainable European induced pluripotent stem cell platform
  • Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
  • Human tumour microenvironment immunoprofiling
  • ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
  • Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
  • Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • Pilot programme on a clinical compound bank for repurposing: cardiovascular diseases and diabetes
  • Pilot programme on a clinical compound bank for repurposing: respiratory diseases
  • Pilot programme on a clinical compound bank for repurposing: neurodegenerative diseases
  • Pilot programme on a clinical compound bank for repurposing: rare/orphan diseases

More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents can be found on the IMI2 Call documents page.

 

Projects

The projects resulting from IMI2 – Call 13 are:

  • MOBILISE-D - Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
  • IMMUCAN - Integrated immunoprofiling of large adaptive cancer patients cohorts
  • CONCEPTION - Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
  • TransBioLine - Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • BIOMAP - Biomarkers in atopic dermatitis and psoriasis
  • VALUE-Dx - The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
  • CARDIATEAM - Cardiomyopathy in type 2 diabetes mellitus
  • NeuroDeRisk - Neurotoxicity de-risking in preclinical drug discovery
  • EBiSC2 – A sustainable European bank for induced pluripotent stem cells
  • PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
  • NEURONET - Efficiently networking European neurodegeneration research
  • STOPFOP - Saracatinib trial to prevent FOP
  • PD-MIND - Parkinson disease with mild cognition impairment treated with nicotinic agonist drug

 

Call statistics

  • Proposals submitted: 38
  • Inadmissible & ineligible proposals: 2
  • Proposals recommended for funding: 13
  • Proposals not recommended for funding: 23

 

Reports